Telix Pharmaceuticals (TLPPF) Receivables (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Receivables for 4 consecutive years, with $606.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables changed N/A year-over-year to $606.4 million in Q2 2026; TTM through Jun 2026 was $606.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $129.2 million, up 41.47% from the prior year.
• Receivables was $606.4 million for Q2 2026 at Telix Pharmaceuticals, up from $129.2 million in the prior quarter.
• Over five years, Receivables peaked at $606.4 million in Q2 2026 and troughed at $42.5 million in Q4 2023.
• A 4-year average of $217.4 million and a median of $110.3 million in 2024 frame the typical range for Receivables.
• Across the five-year window, Receivables surged 114.81% in 2024 and surged 41.47% in 2025, its largest moves.
• Over 4 years, Receivables stood at $42.5 million in 2023, then soared by 114.81% to $91.3 million in 2024, then soared by 41.47% to $129.2 million in 2025, then soared by 369.37% to $606.4 million in 2026.
• The last three Receivables figures came in at $606.4 million (Q2 2026), $129.2 million (Q4 2025), and $91.3 million (Q4 2024), per Business Quant data.